Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong revenue growth in several segments and improved margins are positive, but significant customer loss and increased expenses are concerning. The optimistic guidance and strategic initiatives in AI and genomics are promising, yet the conservative revenue loss estimate and expected cash burn are potential negatives. The Q&A reveals management's confidence in future growth but lacks clarity on cost synergies and AI strategy. Given these factors, the stock price reaction is likely to be neutral over the next two weeks.
Key Financial Performance
Fourth Quarter Revenue $83.3 million, an increase of 9% year-over-year, but a slight decrease quarter-over-quarter. The decrease was primarily due to lower-than-anticipated volume from the largest customer transitioning testing in-house.
Full Year Revenue $322.7 million, a 14% increase year-over-year. Growth was driven by investments in AI and digital pathology solutions, as well as product innovations.
Precision Diagnostics Revenue (Q4) $48.2 million, an increase of 11% year-over-year, but down 5% sequentially. The decline was due to lower-than-anticipated volume from the largest customer transitioning testing in-house.
AP Revenue (Q4) $27 million, an increase of 3% year-over-year and up 4% sequentially.
Biopharma Services Revenue (Q4) $8.1 million, an increase of 32% year-over-year and 10% sequentially.
Precision Diagnostics Revenue (Full Year) $190.5 million, a 14% increase over 2024.
AP Revenue (Full Year) $106.4 million, a 10% increase over 2024.
Biopharma Services Revenue (Full Year) $25.8 million, a 58% increase over 2024.
Gross Margin (Q4) Non-GAAP basis: 41%, GAAP basis: 39.1%. Full year gross margins improved year-over-year due to streamlined operations and enhanced efficiencies from scaling and centralizing lab operations.
GAAP Operating Expenses (Q4) $68.8 million, an increase from $50.9 million in the prior quarter. The increase was driven by acquisition-related costs, payroll-related expenses, and a one-time professional liability expense.
Non-GAAP Operating Expenses (Q4) $43.1 million, compared to $40.7 million in the previous quarter.
GAAP Loss (Q4) $23.4 million, an increase from the prior quarter GAAP loss of $6.6 million.
Adjusted EBITDA (Q4) Loss of approximately $4.5 million, compared to a gain of $700,000 in Q3 2025.
Non-GAAP Income (Q4) Approximately $5.2 million or $0.16 per share, excluding equity-based compensation expense, intangible asset amortization, acquisition-related costs, and a one-time professional liability expense.
Non-GAAP Income (Full Year) Approximately $13.2 million or $0.42 per share, excluding equity-based compensation expense, intangible asset amortization, acquisition-related costs, and a one-time professional liability expense.
Cash Position (End of Q4) Approximately $705.5 million in cash, cash equivalents, restricted cash, and marketable securities. The decrease from the previous quarter was due to the purchase of income tax credits and capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Proprietary Imaging Management System (Eziopath): Launched Eziopath, integrating in-house developed AI tools for enhanced control in technology services.
RNA Integrated Whole Genome Sequencing and Ultra-Rapid Whole Genome Sequencing: Introduced these innovative sequencing products in 2025.
Acquisition of Bako Diagnostics and StrataDx: Pending regulatory approval for a $55.5 million acquisition to expand anatomic pathology services and client base.
New York State Approvals: Received approval for proprietary NIPT offering (Nova) and whole genome sequencing test, opening new market opportunities in New York.
AI and Digital Pathology Investments: Achieved 100% digital pathology operations with Eziopath, improving efficiency and precision.
Revenue Growth: 2025 revenue increased by 14% year-over-year to $322.7 million, driven by double-digit growth across business areas.
Therapeutic Development Pipeline: Progressed FID-007 to Phase II with promising efficacy and safety data; Phase III initiation planned for 2027. FID-022 advancing through Phase I for solid tumors.
Customer Transition Impact: Largest customer moving significant volume in-house, impacting 2026 revenue, but offset by strategic acquisitions and investments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Customer Transition: The company's largest customer is moving significant testing volume in-house, which is expected to sharply reduce revenue from this customer in the first half of 2026. This customer accounted for 22% of total revenue in 2025, creating a significant impact on revenue concentration and financial performance.
Revenue Decline: The company experienced a slight revenue shortfall in 2025 compared to updated expectations, and the first half of 2026 is expected to see further revenue challenges due to customer transition and other factors.
Acquisition Risks: The planned acquisitions of Bako Diagnostics and StrataDx, while potentially beneficial, carry risks related to regulatory approvals, integration challenges, and achieving expected performance levels.
Operating Margin Pressure: Non-GAAP operating margins are expected to decrease significantly in 2026, driven by incremental expenses from acquisitions, investments in sales and R&D, and changes in customer composition.
Biopharma Revenue Decline: Biopharma revenue is expected to decrease from $25.8 million in 2025 to $20 million in 2026, reflecting challenges in the long sales cycle and market dynamics.
Regulatory and Approval Delays: The company has faced delays in receiving a $106 million federal income tax refund due to a government shutdown, which could impact cash flow and financial planning.
Therapeutic Development Costs: The company plans to spend approximately $26 million in 2026 on therapeutic development, which could strain financial resources if expected returns are not realized.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Investment in AI and Digital Pathology: The company has implemented best-in-class technology across its platform, including digital pathology and AI-enabled workflows, which have improved quality, turnaround time, and throughput. Proprietary imaging management system, Eziopath, integrates in-house AI tools for greater control.
Product Innovation: Launched RNA integrated whole genome sequencing and ultra-rapid whole genome sequencing in 2025.
Therapeutic Development: Progressed FID-007 to Phase II with 46 patients enrolled and plans for Phase III initiation in 2027. FID-022 is in Phase I dose escalation with completion expected in 2026.
Acquisitions: Announced intention to acquire Bako Diagnostics and StrataDx for $55.5 million, adding new anatomic pathology services and expanding the national client base.
AI R&D Pipeline: Plans to develop a dozen AI modules in 2026 to improve operational efficiency and enhance diagnostic capabilities, particularly in oncology.
Revenue Impact from Largest Customer: Revenue in the first half of 2026 will be impacted by the largest customer moving significant volume in-house, with stabilization expected in the second half.
Revenue Growth Projections: Total revenue for 2026 is projected to be approximately $350 million, representing 8.5% year-over-year growth. Precision Diagnostics is expected to grow by 31%, and anatomic pathology revenue is projected to increase by 53%.
Gross Margins: Non-GAAP gross margins for 2026 are expected to be slightly above 40%, with lower margins in the first half due to changes in customer composition.
Operating Margins: Non-GAAP operating margins are expected to decrease to minus 18% for 2026, driven by acquisition-related expenses and investments in R&D and sales expansion.
Therapeutic Development Spending: Approximately $26 million will be allocated to advancing clinical trials for FID-002 and FID-007 in 2026.
Cash Position: The company expects to end 2026 with approximately $685 million in cash, assuming the receipt of delayed tax refunds and excluding extraordinary expenditures.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you confirm the revenue loss for your largest customer in 2026 and explain how conservative this estimate is?
A:The revenue from the largest customer was $70.8 million in 2025, and for 2026, the company expects $11.8 million, resulting in a $59 million loss. This estimate is considered conservative, with good visibility into the numbers and some contractual commitments still in place.
Q:How do you plan to grow your customer pipeline and your own brand diagnostics?
A:The company plans to grow through several drivers, including expanding market share for the Beacon test, investing in whole genome sequencing bundled with RNA sequencing, and leveraging the MolDX-approved somatic assay branded Lumera. They are also expanding their sales team and focusing on genetics' growing role in healthcare, such as DPYD testing for chemotherapy patients.
Q:What is your capital allocation strategy, and are you planning more acquisitions?
A:The company is focusing on AI capabilities and looking for synergies with companies providing AI-enabled discoveries. They are balancing this with organic investments.
Q:Can you confirm if the loss of the largest customer will be a gross margin headwind and if there are cost synergies associated with running your own carrier screening project?
A:Yes, the loss of the largest customer will be a gross margin headwind, with gross margins expected to decrease in the first half of 2026 but rebound significantly in the second half. There are no additional customers greater than 10% of revenue, and the company is leveraging its expanded sales team for synergies.
Q:How did Beacon Carrier Screening perform, and what are your expectations for 2026?
A:Beacon has performed well, though some volume was impacted by the large customer loss. The organic Beacon volume and pipeline remain strong, and it is expected to be a key growth driver in 2026.
Q:What are the cash burn dynamics for 2026, and how do they compare to expectations?
A:The company expects a cash burn of approximately $33 million for the year, slightly higher than anticipated due to operating expenses from the Bako acquisition. They ended 2025 with $800 million in cash and forecast $685 million by the end of 2026, with significant outlays for acquisitions and other investments.
Q:What is the impact of digital pathology on your operations, and how will it integrate with recent acquisitions?
A:Digital pathology improves efficiency, reduces errors, and enhances AI training. The company plans to bring these capabilities to Bako and StrataDx, increasing capacity and leveraging synergies between sales teams.
Q:Are you rightsized for the business after the loss of the large customer?
A:The company has kept headcount relatively flat for 2026, with nominal increases in sales. They view the customer loss as a one-time event and believe in their growth trajectory, maintaining their current organizational structure.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact areas targeted for AI-enabled acquisitions and did not elaborate on the potential cost savings or operational adjustments following the loss of the large customer.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI RD
AI module
AI technology
Bako Diagnostics
Biopharma Services
CLIA CAP
Diagnostics increase
Eziopath party
FDA
New York
Phase III
Services increase
State
StrataDx
approval
class
client base
customer volume
dose level
efficacy
house
increase Biopharma
innovation
investment AI
pathology service
platform investment
provider
service product
service testing
specialty
system Eziopath
technology service
treatment head
FLGT Transcript
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call reveals several negative factors: a significant decline in revenue, reduced gross margins, increased losses, and a major customer's transition impacting sales. Despite management's confidence in margin recovery and ongoing product development, the financial performance remains weak. The Q&A section showed uncertainty regarding future growth and a lack of clarity on strategic impacts, such as the CMS CRUSH initiative. While share repurchases and cash reserves are positive, they don't offset the broader negative sentiment. Given these factors, a negative stock price movement is likely in the short term.
Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call presents a mixed picture: strong revenue growth in several segments and improved margins are positive, but significant customer loss and increased expenses are concerning. The optimistic guidance and strategic initiatives in AI and genomics are promising, yet the conservative revenue loss estimate and expected cash burn are potential negatives. The Q&A reveals management's confidence in future growth but lacks clarity on cost synergies and AI strategy. Given these factors, the stock price reaction is likely to be neutral over the next two weeks.
Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call indicates strong financial performance with improved gross margins, reduced operating expenses, and a positive adjusted EBITDA. Revenue guidance has been raised, and there is optimism about future growth due to new product launches and market expansion. While management avoided specific guidance on some aspects, the overall sentiment is positive due to strategic advancements and financial health improvements. The Q&A session provided reassurance on collection issues and highlighted growth drivers, supporting a positive outlook for stock price movement.
FLGT Slides
FLGT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
